- Home
- MCI vs INBX Comparison
MCI vs INBX Comparison
Compare MCI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCI
- INBX
- Stock Information
- Founded
- MCI 1971
- INBX 2010
- Country
- MCI United States
- INBX United States
- Employees
- MCI N/A
- INBX N/A
- Industry
- MCI Trusts Except Educational Religious and Charitable
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- MCI Finance
- INBX Health Care
- Exchange
- MCI Nasdaq
- INBX Nasdaq
- Market Cap
- MCI 419.4M
- INBX 430.2M
- IPO Year
- MCI N/A
- INBX 2020
- Fundamental
- Price
- MCI $20.38
- INBX $33.88
- Analyst Decision
- MCI
- INBX Hold
- Analyst Count
- MCI 0
- INBX 2
- Target Price
- MCI N/A
- INBX N/A
- AVG Volume (30 Days)
- MCI 40.4K
- INBX 123.8K
- Earning Date
- MCI 01-01-0001
- INBX 11-13-2025
- Dividend Yield
- MCI 8.46%
- INBX N/A
- EPS Growth
- MCI N/A
- INBX N/A
- EPS
- MCI 1.82
- INBX N/A
- Revenue
- MCI N/A
- INBX $1,400,000.00
- Revenue This Year
- MCI N/A
- INBX $563.00
- Revenue Next Year
- MCI N/A
- INBX $230.77
- P/E Ratio
- MCI $9.88
- INBX N/A
- Revenue Growth
- MCI N/A
- INBX N/A
- 52 Week Low
- MCI $12.96
- INBX $10.81
- 52 Week High
- MCI $19.24
- INBX $37.53
- Technical
- Relative Strength Index (RSI)
- MCI 42.44
- INBX 70.20
- Support Level
- MCI $20.44
- INBX $31.75
- Resistance Level
- MCI $20.82
- INBX $37.53
- Average True Range (ATR)
- MCI 0.60
- INBX 1.99
- MACD
- MCI -0.10
- INBX 0.27
- Stochastic Oscillator
- MCI 9.22
- INBX 67.38
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.